{"database": "openregs", "table": "documents", "is_view": false, "human_description_en": "where docket_id = \"FDA-2013-N-1524\" and posted_year = 2014 sorted by posted_date descending", "rows": [["FDA-2013-N-1524-1369", "FDA", "FDA-2013-N-1524", "Attachments G through H Catalyst Pharmaceutical Partners Inc. Press Releases re Request for Nomination from Catalyst Pharmaceutical Partners Inc.", "Supporting & Related Material", "Background Material", "2014-11-10T05:00:00Z", 2014, 11, null, null, "2014-11-10T17:09:43Z", null, 0, 0, "090000648191ccb6"], ["FDA-2013-N-1524-1367", "FDA", "FDA-2013-N-1524", "Attachment B Aminopyridine Review FDA Compounding Advisory Committee General Comments re Request for Nomination from Catalyst Pharmaceutical Partners Inc.", "Supporting & Related Material", "Background Material", "2014-11-10T05:00:00Z", 2014, 11, null, null, "2014-11-10T17:03:27Z", null, 0, 0, "090000648191cc1b"], ["FDA-2013-N-1524-1366", "FDA", "FDA-2013-N-1524", "Attachment A Pharmacy Compounding Advisory Committee Meetng Minutes May 6 and 7, 1999 re Request for Nomination from Catalyst Pharmaceutical Partners Inc.", "Supporting & Related Material", "Background Material", "2014-11-10T05:00:00Z", 2014, 11, null, null, "2014-11-10T17:02:10Z", null, 0, 0, "090000648191cc19"], ["FDA-2013-N-1524-1368", "FDA", "FDA-2013-N-1524", "Attachment C May 6, 1999 Pharmacy Compounding Advisory Committee Meeting re Request for Nomination from Catalyst Pharmaceutical Partners Inc.", "Supporting & Related Material", "Background Material", "2014-11-10T05:00:00Z", 2014, 11, null, null, "2014-11-10T17:04:46Z", null, 0, 0, "090000648191cc1d"], ["FDA-2013-N-1524-0682", "FDA", "FDA-2013-N-1524", "Letter from Gary Gray to California State Board of Pharmacy Dated August 18, 2014 RE: Request for Nomination from Gary Gray Pharmacist dba COMPLEX", "Supporting & Related Material", "Background Material", "2014-09-16T04:00:00Z", 2014, 9, null, null, "2014-10-06T17:53:32Z", null, 0, 0, "090000648185e5e6"], ["FDA-2013-N-1524-0683", "FDA", "FDA-2013-N-1524", "National Plan to Address Alzheimer's Disease RE: Request for Nomination from Gary Gray Pharmacist dba COMPLEX", "Supporting & Related Material", "Background Material", "2014-09-16T04:00:00Z", 2014, 9, null, null, "2014-09-17T00:00:36Z", null, 0, 0, "090000648185e5e7"], ["FDA-2013-N-1524-0685", "FDA", "FDA-2013-N-1524", "Summary of  Pharmaclogical Drug Information RE: Request for Nomination from Gary Gray Pharmacist dba COMPLEX", "Supporting & Related Material", "Background Material", "2014-09-16T04:00:00Z", 2014, 9, null, null, "2014-09-17T00:11:08Z", null, 0, 0, "090000648185e5ea"], ["FDA-2013-N-1524-0687", "FDA", "FDA-2013-N-1524", "Cited Reference Martin-Moreno et al Prolonged Oral Cannabinoid Administration Prevents Neuroinflammation Lowers b-amyloid\nLevels and Improves Cognitive Performance in Tg APP 2576 mice RE: Request for Nomination from Gary Gray Pharmacist dba COMPLEX", "Supporting & Related Material", "Background Material", "2014-09-16T04:00:00Z", 2014, 9, null, null, "2014-10-06T18:21:28Z", null, 0, 0, "090000648185e5f6"], ["FDA-2013-N-1524-0688", "FDA", "FDA-2013-N-1524", "Business Plan and Credentials from Gary Gray dba Complex RE: Request for Nomination from Gary Gray Pharmacist dba COMPLEX", "Supporting & Related Material", "Background Material", "2014-09-16T04:00:00Z", 2014, 9, null, null, "2014-10-06T18:24:27Z", null, 0, 0, "090000648185e5f7"], ["FDA-2013-N-1524-0686", "FDA", "FDA-2013-N-1524", "Letter from Gary Gray to DEA DOJ Dated August 12, 2014 RE: Request for Nomination from Gary Gray Pharmacist dba COMPLEX", "Supporting & Related Material", "Background Material", "2014-09-16T04:00:00Z", 2014, 9, null, null, "2014-09-17T00:10:44Z", null, 0, 0, "090000648185e5eb"], ["FDA-2013-N-1524-0684", "FDA", "FDA-2013-N-1524", "California State Board of Pharmacy Community Pharmacy Permit Application from Gary Gray RE: Request for Nomination from Gary Gray Pharmacist dba COMPLEX", "Supporting & Related Material", "Background Material", "2014-09-16T04:00:00Z", 2014, 9, null, null, "2014-09-17T00:07:06Z", null, 0, 0, "090000648185e5e8"], ["FDA-2013-N-1524-0690", "FDA", "FDA-2013-N-1524", "503A Pharmacy Compounded Drug Product Nomination July 2014 Guidance CDER at FDA RE: Request for Nomination from Gary Gray Pharmacist dba COMPLEX", "Supporting & Related Material", "Background Material", "2014-09-16T04:00:00Z", 2014, 9, null, null, "2014-09-17T00:20:16Z", null, 0, 0, "090000648185e5fa"], ["FDA-2013-N-1524-0680", "FDA", "FDA-2013-N-1524", "Cited Reference The Endocannabinoid System as an Emerging Target\r\nof Pharmacotherapy Pacher et al RE: Request for Nomination from Gary Gray Pharmacist dba COMPLEX", "Supporting & Related Material", "Background Material", "2014-09-15T04:00:00Z", 2014, 9, null, null, "2014-09-17T00:28:46Z", null, 0, 0, "090000648185e5e9"], ["FDA-2013-N-1524-0298", "FDA", "FDA-2013-N-1524", "Bulk Drug Substances That May Be Used To Compound Drug Products in\nAccordance With Section 503B of the Federal Food, Drug, and Cosmetic Act, Concerning Outsourcing Facilities; Revised Request for Nominations", "Notice", "Request for Nominations", "2014-07-02T04:00:00Z", 2014, 7, "2014-07-02T04:00:00Z", "2014-10-01T03:59:59Z", "2015-07-23T01:30:24Z", "2014-15373", 0, 0, "090000648178723a"]], "truncated": false, "filtered_table_rows_count": 14, "expanded_columns": [], "expandable_columns": [[{"column": "docket_id", "other_table": "dockets", "other_column": "id"}, "title"]], "columns": ["id", "agency_id", "docket_id", "title", "document_type", "subtype", "posted_date", "posted_year", "posted_month", "comment_start_date", "comment_end_date", "last_modified", "fr_doc_num", "open_for_comment", "withdrawn", "object_id"], "primary_keys": ["id"], "units": {}, "query": {"sql": "select id, agency_id, docket_id, title, document_type, subtype, posted_date, posted_year, posted_month, comment_start_date, comment_end_date, last_modified, fr_doc_num, open_for_comment, withdrawn, object_id from documents where \"docket_id\" = :p0 and \"posted_year\" = :p1 order by posted_date desc limit 101", "params": {"p0": "FDA-2013-N-1524", "p1": "2014"}}, "facet_results": {"agency_id": {"name": "agency_id", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?docket_id=FDA-2013-N-1524&posted_year=2014", "results": [{"value": "FDA", "label": "FDA", "count": 14, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2013-N-1524&posted_year=2014&agency_id=FDA", "selected": false}], "truncated": false}, "document_type": {"name": "document_type", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?docket_id=FDA-2013-N-1524&posted_year=2014", "results": [{"value": "Supporting & Related Material", "label": "Supporting & Related Material", "count": 13, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2013-N-1524&posted_year=2014&document_type=Supporting+%26+Related+Material", "selected": false}, {"value": "Notice", "label": "Notice", "count": 1, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2013-N-1524&posted_year=2014&document_type=Notice", "selected": false}], "truncated": false}, "posted_year": {"name": "posted_year", "type": "column", "hideable": false, "toggle_url": "/openregs/documents.json?docket_id=FDA-2013-N-1524&posted_year=2014", "results": [{"value": 2014, "label": 2014, "count": 14, "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2013-N-1524", "selected": true}], "truncated": false}}, "suggested_facets": [{"name": "subtype", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2013-N-1524&posted_year=2014&_facet=subtype"}, {"name": "posted_date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2013-N-1524&posted_year=2014&_facet=posted_date"}, {"name": "posted_month", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2013-N-1524&posted_year=2014&_facet=posted_month"}, {"name": "posted_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2013-N-1524&posted_year=2014&_facet_date=posted_date"}, {"name": "comment_start_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2013-N-1524&posted_year=2014&_facet_date=comment_start_date"}, {"name": "comment_end_date", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2013-N-1524&posted_year=2014&_facet_date=comment_end_date"}, {"name": "last_modified", "type": "date", "toggle_url": "https://www.pawtectors.org/openregs/documents.json?docket_id=FDA-2013-N-1524&posted_year=2014&_facet_date=last_modified"}], "next": null, "next_url": null, "private": false, "allow_execute_sql": true, "query_ms": 784.3574129510671, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}